This is PART 1 of the 8-hour Buprenorphine Training
(PART 2 will be available to you once it has been verified that PART 1 has been completed in its entirety of 4.25-hours)

NOTE: This training has a starting time of 8:00 AM Eastern Time.
Please check your time zone for start time and download the Zoom app prior to training. https://zoom.us/ent?zcid=2582

The 1st half of the training is a 4.25-hour live webcast. The 2nd half of the course is a 3.75-hour on-your-own online study. Part 2 Instructions will be provided ONLY to participants who complete Part 1 in its entirety. This will be sent via email and will also become available on the AOAAM learner software once your certificate of CME has been claimed.

You must be both online viewing and listening to the presentation. Participation in the interactive polling questions is also required in order for the AOAAM to verify attendance. PHONE ONLY PARTICIPATION DOES NOT QUALIFY FOR CREDIT.

This training will count towards the DEA’s 8-hour training requirement when applying for or renewing your DEA license.

Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent and obtain a waiver to your DEA license to prescribe schedule III-V medications, approved by the FDA for the treatment of opioid use disorder (OUD).

The Consolidated Appropriations Act of 2023 enacted a new one-time, eight-hour training requirement for all Drug Enforcement Administration (DEA)-registered practitioners on the treatment and management of patients with opioid or other substance use disorders.

Beginning on June 27, 2023, practitioners will be required to check a box on their online DEA registration form, affirming that they have completed the new training requirement.

• To understand the federal Drug Abuse Treatment Act (DATA) of 2000 and the subsequent revisions that lists the criteria needed for Office Based Opioid Treatment (OBOT) utilizing buprenorphine for opioid dependence and the new changes/guidelines
• To distinguish between spontaneous withdrawal and precipitated withdrawal and the appropriate methods of buprenorphine induction
• To describe and contrast the functions of full mu agonists, partial agonists and antagonists
• To describe the basic approach used in at least three different types of non-pharmacological treatment of opioid dependence
• To describe three symptoms of opioid withdrawal or intoxication that mimic symptoms of a psychiatric disorder
• To list the criteria for establishing the diagnosis of opioid dependence
• To list at least three situations in which patient information, with patient identity, can be shared under current laws protecting the patient’s confidentiality
• To understand and minimize buprenorphine misuse and diversion. To be aware of the issues of drug interactions of buprenorphine and pediatric exposures

This course has been reviewed and is acceptable for 4.25 credits of AOA Category 1A by the AOA CCME. It has also been reviewed and is acceptable for 4.25 Prescribed credit(s) by the American Academy of Family Physicians.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed credit, not as Category 1.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Stephen A. Wyatt, D.O, is a Board-Certified Psychiatrist with added subspecialty certification in Addiction Psychiatry. He completed his residency at University Hospitals of Cleveland and then entered a NIDA clinical research fellowship in addiction psychiatry at the Yale School of Medicine. He is an adjunct clinical faculty member of the University of North Carolina. He is a past president of the AOAAM.  He is the current Chairman of the NC Psychiatric Asso. Addiction Psychiatry Committee and the Vice Chair of the Coalition on Physician Education in Substance Use Disorders a national organization focused on addiction medicine medical school education. He was the Co-Chair for the 2020 focused update of the ASAM Clinical Guidelines for Office Based Opioid Treatment. He is a clinical expert for the SAMHSA funded Provider Clinical Support System, PCSS; Medication Assisted Treatment and Implementation Projects.